{
    "info": {
        "nct_id": "NCT04467801",
        "official_title": "A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)",
        "inclusion_criteria": "* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent\n* Life expectancy ≥12 weeks\n* Males and females age ≥ 18 years\n* Allowable type and amount of prior therapy:\n\nFirst line anti-Programmed death receptor and ligand (PD1/PD-L1), either single agent or in combination with chemotherapy\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n* Measurable disease per RECIST version 1.1\n* Diagnoses of advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy, and have either exhausted or decline or not be candidates for all available standard of care therapies.\n* Adequate organ function\n* Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy\n* Men of child-bearing potential must agree not to donate sperm while on this study and for 90 days after their last study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study\n* Is not currently on or is not anticipated to use other investigational agents within 14 days prior to and while participating in this study\n* Does not have mixed small cell and non-small cell lung cancer histology\n* Does not have any unresolved toxicity CTCAE >Grade 2 from the prior 1st immunotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included\n* Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded from this study\n* Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment, depending on the agent and during study treatment, until disease progression is documented and the patient has discontinued study treatment, with the exception of palliative radiotherapy and local therapy per PI discretion\n* Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) inhibitor or inducer, or sensitive CYP3A substrates with a narrow therapeutic window\n* Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug\n* Does not have uncontrolled systemic disease\n* Does not have uncontrolled brain metastasis\n* Does not have history of allergy to taxanes\n* Does not have history of leptomeningeal carcinomatosis\n* Does not have recent history of myocardial infarction (MI) or symptomatic coronary artery disease within 6 months of screening\n* Is not receiving active therapy for HIV, hepatitis B or hepatitis C\n* Does not have history of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills\n* Does not have history of Type I or Type II diabetes mellitus requiring insulin (Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment\n* Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia\n* Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)\n* Does not have active pneumonitis\n* Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections\n* Does not have uncontrolled pleural effusion/pericardial effusion/or ascites as determined by the investigator\n* Does not have active ventricular arrhythmia requiring medication\n* Does not have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent\n* Is not pregnant, breast feeding or planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment\n* For males with partners of childbearing potential, is not planning to father a child or donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment\n* Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential ... must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy",
                    "criterion": "women of child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to contraception or abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception or abstinence",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study participation"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days after therapy"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy",
                    "criterion": "men with partners of child-bearing potential",
                    "requirements": [
                        {
                            "requirement_type": "agreement to contraception or abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception or abstinence",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study participation"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days after therapy"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allowable type and amount of prior therapy:",
            "criterions": [
                {
                    "exact_snippets": "Allowable type and amount of prior therapy",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "allowable types (to be specified elsewhere)"
                        },
                        {
                            "requirement_type": "amount",
                            "expected_value": "allowable amount (to be specified elsewhere)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Males and females age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Males and females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men of child-bearing potential must agree not to donate sperm while on this study and for 90 days after their last study treatment",
            "criterions": [
                {
                    "exact_snippets": "Men of child-bearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree not to donate sperm while on this study and for 90 days after their last study treatment",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "First line anti-Programmed death receptor and ligand (PD1/PD-L1), either single agent or in combination with chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "anti-Programmed death receptor and ligand (PD1/PD-L1)",
                    "criterion": "anti-PD1/PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "either single agent or in combination with chemotherapy",
                    "criterion": "anti-PD1/PD-L1 therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "regimen type",
                            "expected_value": [
                                "single agent",
                                "in combination with chemotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnoses of advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy, and have either exhausted or decline or not be candidates for all available standard of care therapies.",
            "criterions": [
                {
                    "exact_snippets": "Diagnoses of advanced/metastatic NSCLC",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy",
                    "criterion": "1st line anti-PD1/PD-L1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": [
                                "failed",
                                "intolerant"
                            ]
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "single agent",
                                "in combination with chemotherapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have either exhausted or decline or not be candidates for all available standard of care therapies",
                    "criterion": "standard of care therapies",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": [
                                "exhausted",
                                "decline",
                                "not be candidates"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST version 1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST version 1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Ability of participant OR Legally Authorized Representative (LAR) to understand this study",
                    "criterion": "participant or LAR understanding of the study",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participant or LAR willingness to sign a written informed consent",
                    "criterion": "participant or LAR willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness to sign",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study",
            "criterions": [
                {
                    "exact_snippets": "Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study",
                    "criterion": "concurrent enrollment in another clinical study",
                    "requirements": [
                        {
                            "requirement_type": "enrollment status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "observational (non-interventional) clinical study",
                                "follow-up period of an interventional study"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have mixed small cell and non-small cell lung cancer histology",
            "criterions": [
                {
                    "exact_snippets": "Does not have mixed small cell and non-small cell lung cancer histology",
                    "criterion": "lung cancer histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "not mixed small cell and non-small cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have any unresolved toxicity CTCAE >Grade 2 from the prior 1st immunotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included",
            "criterions": [
                {
                    "exact_snippets": "Does not have any unresolved toxicity CTCAE >Grade 2 from the prior 1st immunotherapy",
                    "criterion": "unresolved toxicity from prior 1st immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included",
                    "criterion": "irreversible toxicity",
                    "requirements": [
                        {
                            "requirement_type": "expected exacerbation by study drug",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have uncontrolled systemic disease",
            "criterions": [
                {
                    "exact_snippets": "Does not have uncontrolled systemic disease",
                    "criterion": "systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results",
            "criterions": [
                {
                    "exact_snippets": "Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results",
                    "criterion": "any condition interfering with evaluation or interpretation of patient safety or study results",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "investigator opinion",
                            "expected_value": "would interfere with evaluation or interpretation of patient safety or study results"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) inhibitor or inducer, or sensitive CYP3A substrates with a narrow therapeutic window",
            "criterions": [
                {
                    "exact_snippets": "Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) inhibitor",
                    "criterion": "chronic use of strong CYP3A4/5 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) ... inducer",
                    "criterion": "chronic use of strong CYP3A4/5 inducer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not chronically use ... sensitive CYP3A substrates with a narrow therapeutic window",
                    "criterion": "chronic use of sensitive CYP3A substrates with a narrow therapeutic window",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other condition that would interfere with enteral absorption",
                    "criterion": "condition interfering with enteral absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "results in the inability ... to swallow pills",
                    "criterion": "inability to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "results in the ... unwillingness to swallow pills",
                    "criterion": "unwillingness to swallow pills",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of leptomeningeal carcinomatosis",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of leptomeningeal carcinomatosis",
                    "criterion": "history of leptomeningeal carcinomatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of allergy to taxanes",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of allergy to taxanes",
                    "criterion": "allergy to taxanes",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have active ventricular arrhythmia requiring medication",
            "criterions": [
                {
                    "exact_snippets": "Does not have active ventricular arrhythmia requiring medication",
                    "criterion": "ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "requirement for medication",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis)",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "active",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active bowel inflammation (e.g., diverticulitis)",
                    "criterion": "bowel inflammation",
                    "requirements": [
                        {
                            "requirement_type": "active",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is not pregnant, breast feeding or planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Is not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment",
                    "criterion": "pregnancy intention during and after treatment",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant during study treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "intention to become pregnant for less than 90 days after the last dose of study treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have uncontrolled brain metastasis",
            "criterions": [
                {
                    "exact_snippets": "Does not have uncontrolled brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of Type I or Type II diabetes mellitus requiring insulin (Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of Type I or Type II diabetes mellitus requiring insulin",
                    "criterion": "history of Type I or Type II diabetes mellitus requiring insulin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment",
                    "criterion": "stable dose of oral diabetes medication",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is not receiving active therapy for HIV, hepatitis B or hepatitis C",
            "criterions": [
                {
                    "exact_snippets": "Is not receiving active therapy for HIV",
                    "criterion": "active therapy for HIV",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Is not receiving active therapy for ... hepatitis B",
                    "criterion": "active therapy for hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Is not receiving active therapy for ... hepatitis C",
                    "criterion": "active therapy for hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections",
            "criterions": [
                {
                    "exact_snippets": "Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections",
                    "criterion": "history of interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have history of lung disease: ... idiopathic pulmonary fibrosis",
                    "criterion": "history of idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have history of lung disease: ... cystic fibrosis",
                    "criterion": "history of cystic fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have history of lung disease: ... Aspergillosis",
                    "criterion": "history of Aspergillosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have history of lung disease: ... active tuberculosis",
                    "criterion": "history of active tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have ... history of opportunistic infections",
                    "criterion": "history of opportunistic infections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have uncontrolled pleural effusion/pericardial effusion/or ascites as determined by the investigator",
            "criterions": [
                {
                    "exact_snippets": "Does not have uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have uncontrolled ... ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment, depending on the agent and during study treatment, until disease progression is documented and the patient has discontinued study treatment, with the exception of palliative radiotherapy and local therapy per PI discretion",
            "criterions": [
                {
                    "exact_snippets": "Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment",
                    "criterion": "concomitant cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration prior to study treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not on concomitant therapy intended for the treatment of cancer ... during study treatment, until disease progression is documented and the patient has discontinued study treatment",
                    "criterion": "concomitant cancer therapy during study treatment",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of palliative radiotherapy and local therapy per PI discretion",
                    "criterion": "palliative radiotherapy and local therapy",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug",
            "criterions": [
                {
                    "exact_snippets": "Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access)",
                    "criterion": "recent major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "major surgery"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "placement of vascular access"
                        }
                    ]
                },
                {
                    "exact_snippets": "that would prevent administration of study drug",
                    "criterion": "ability to receive study drug",
                    "requirements": [
                        {
                            "requirement_type": "administration possible",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded from this study",
            "criterions": [
                {
                    "exact_snippets": "Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded",
                    "criterion": "targetable mutations qualifying for targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have active pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Does not have active pneumonitis",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is not currently on or is not anticipated to use other investigational agents within 14 days prior to and while participating in this study",
            "criterions": [
                {
                    "exact_snippets": "Is not currently on ... other investigational agents",
                    "criterion": "use of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "is not anticipated to use other investigational agents within 14 days prior to and while participating in this study",
                    "criterion": "use of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "anticipated use within 14 days prior to study",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "anticipated use during study participation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For males with partners of childbearing potential, is not planning to father a child or donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "For males with partners of childbearing potential",
                    "criterion": "male participant's partner childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is not planning to father a child ... while receiving study treatment or for less than 90 days after the last dose of study treatment",
                    "criterion": "plan to father a child",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "is not planning to ... donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment",
                    "criterion": "plan to donate sperm",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Does not have psychiatric illness ... that would limit compliance with study requirements",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "impact on compliance with study requirements",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have ... social situations that would limit compliance with study requirements",
                    "criterion": "social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have psychiatric illness/social situations that would ... compromise the ability of the patient to give written informed consent",
                    "criterion": "psychiatric illness or social situations compromising ability to give written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "impact on ability to give written informed consent",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Does not have recent history of myocardial infarction (MI) or symptomatic coronary artery disease within 6 months of screening",
            "criterions": [
                {
                    "exact_snippets": "Does not have recent history of myocardial infarction (MI) within 6 months of screening",
                    "criterion": "myocardial infarction (MI)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have ... symptomatic coronary artery disease within 6 months of screening",
                    "criterion": "symptomatic coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia",
            "criterions": [
                {
                    "exact_snippets": "Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia",
                    "criterion": "hypercholesterolemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled or untreated"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Does not have Grade greater than or equal to 2 uncontrolled or untreated hypertriglyceridemia",
                    "criterion": "hypertriglyceridemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled or untreated"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}